Connect with us

Business

Series of JAK inhibitor delays may signal an upcoming FDA adcomm – Endpoints News

Three-month review delays from the FDA have become the norm in recent days for JAK inhibitors, some of which are seeking label expansions. But the pushback of these…

Published

on

Article feature image
ADVERTISEMENT

Three-month re­view de­lays from the FDA have be­come the norm in re­cent days for JAK in­hibitors, some of which are seek­ing la­bel ex­pan­sions.
But the push­back of these ac­tion dates for Ab­b­Vie’s Rin­voq, Pfiz­er’s Xel­janz and abroc­i­tinib, and Eli Lil­ly’s Olu­mi­ant may be a sign that the FDA is prepar­ing to hold an ad­vi­so­ry com­mit­tee of out­side ex­perts to re­view the risk/ben­e­fit pro­files of JAK in­hibitors for atopic der­mati­tis, ac­cord­ing to Leerink an­a­lyst Ge­of­frey…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Yellen outlines bold climate agenda calling for net-zero emissions by 2035 – CNBC
Article feature image
If you’re in your 50s or 60s, consider these moves to avoid higher taxes in retirement – MarketWatch
Article feature image
After His Heart Attack, a British Man’s Rules for Living Take Off on LinkedIn – The New York Times